Products for Research Use Only
RegisterLogin

Tunlametinib

CAT: 0804-HY-132844-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-132844-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel. Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer)[2].
CAS Number
1801756-06-8
Product Name Alternative
HL-085
UNSPSC
12352005
Target
MEK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tunlametinib.html
Concentration
10mM
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC2=C(C(F)=C1NC3=CC=C(C=C3F)I)N=CS2)NOCCO
Molecular Formula
C16H12F2IN3O3S
Molecular Weight
491.25
References & Citations
[1]Liu Y, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Front Pharmacol. 2023 Sep 21;14:1271268.|[2]Sari MHM, et al. Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma. Front Oncol. 2024 Apr 4;14:1403778.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
MEK1; MEK2

Alternative Products

CatalogName
T39220-01Tunlametinib
A24217-100Tunlametinib (HL-085) 100mg
A24217-10Tunlametinib (HL-085) 10mg
A24217-5Tunlametinib (HL-085) 5mg
A24217-50Tunlametinib (HL-085) 50mg

Popular Products